NetworkNewsBreaks Archive - Page 2100 of 2113

FridayOct 28, 2016 1:36 pm

Idera Pharmaceuticals, Inc. (IDRA) Widens Loss in Q3, Shares Lower

Idera Pharmaceuticals (NASDAQ: IDRA) posted a third-quarter net loss of $12.9 million, or $(0.10) per basic and diluted share, compared to a net loss of $11.4 million, or $(0.10) per basic and diluted share, for the same period in 2015. Revenue for the 2016 quarter totaled $0.3 million vs. nominal revenue a year ago. To view the full press release, visit: http://nnw.fm/3FPPy About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug…

FridayOct 28, 2016 1:34 pm

Wider Q1 Loss, Lower Sales Drag ImmunoGen, Inc. (IMGN) Shares Lower

ImmunoGen (NASDAQ: IMGN) shares are lower after the company posted a quarterly net loss of $44.7 million, or $(0.51) per basic and diluted share, on revenues of $7.7 million vs. a net loss of $33.7 million, or $(0.39) per basic and diluted share, on revenues of $14.9 million the year prior. To view the full press release, visit: http://nnw.fm/Jgg6N About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing…

FridayOct 28, 2016 1:33 pm

Opexa Therapeutics’ (OPXA) Tcelna Misses Endpoints in MS Study, Shares Plunge

Shares of Opexa Therapeutics (NASDAQ: OPXA) sank 68% in morning trade on news the biopharmaceutical company’s phase 2b Abili-T clinical trial to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) failed to meet primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression. The drug candidate did show a favorable safety and tolerability profile. To view the full press release, visit: http://nnw.fm/eHA99 About Opexa Therapeutics Opexa Therapeutics is a biopharmaceutical company developing personalized immunotherapies based on ImmPath®,…

ThursdayOct 27, 2016 2:03 pm

Cheribum Interests, Inc. (CHIT): BudCube Cultivation Advances Technology Deployment, Shares Climb

Shares Cherubim Interests (OTC: CHIT) are up 8% mid-day, potentially moving from yesterday’s news that its wholly owned subsidiary, BudCube Cultivation Systems USA, has initiated due diligence for its inaugural site location to deploy its BudCube Cultivation Systems Technology. BudCube Cultivation Systems is an expansion-stage alternative construction and real estate development company and developer of a proprietary, fully portable and scalable, Controlled Environment Agriculture Technology that serves as a turnkey solution for cultivators of legal medical and recreational cannabis. "This industry is moving very rapidly … The market is there, the demand is high, but the supply from legal cultivators…

ThursdayOct 27, 2016 2:01 pm

GrowLife, Inc. (PHOT) Board Extends CEO Employment, Shares Retreat from Morning Spike

GrowLife (OTC: PHOT) shares slipped from an early morning spike following news that the company has extended CEO Marco Hegyi’s employment contract for another two years. “Marco Hegyi has led PHOT back to active trading from the Gray Sheet market, effectively maintained positive and constructive relationships with shareholders, customers and suppliers, and enabled PHOT to continue operating through the Company’s most challenging times,” GrowLife Compensation Committee chairman and board member Michael Fasci stated in the news release. “Therefore, with this employment agreement, GrowLife will maintain management continuity for the next two years under Marco’s leadership.” To view the press release,…

ThursdayOct 27, 2016 1:58 pm

Provision Holding, Inc. (PVHO) Posts Higher Revs, Widened Loss for FY2016, Shares Up

Provision Holding (OTCQB: PVHO) is trading higher in mid-day trade after the 3D holographic display technologies provider posted full-year revenues of $5.0 million compared to $575,000 for the prior year ended June 30, 2016. The company attributes the increase to sales and installations of its 3D Savings Center kiosks in retail stores. Installation expenses widened the company’s net loss to $6.2 million, compared to a net loss of $0.8 million for the same period last year. Gross profit for the period was $526,000, nearly double gross profit of $265,000 in the previous year. To view the full press release, visit: http://nnw.fm/HWc1P…

ThursdayOct 27, 2016 1:57 pm

Inventory Increase Pushes EXOlifestyle, Inc. (EXOL) Shares Higher

Shares of EXOlifestyle (OTCQB: EXOL) climbed 9% in mid-day trade on news of the company’s inventory expansion. The developer of innovative and healthy brands within the health and wellness industry this morning announced that to meet rising demand of its products, it has ordered additional inventory with a retail value of $400,000. To view the full press release, visit: http://nnw.fm/X3yBD About EXOlifestyle Inc. EXOlifestyle Inc. is a management firm which develops and operates innovative and healthy brands within the health & wellness industry with a strong focus on athletic apparel. EXO is a functional sports apparel brand, and designer and producer of active wear products…

ThursdayOct 27, 2016 12:26 pm

Harris & Harris Group, Inc. (TINY): Mersana’s Oncology Drug Candidate Cleared by FDA

Harris & Harris Group (NASDAQ: TINY) focuses on investments in transformative life science companies. Among the company’s portfolio of such investments is Mersana Therapeutics, Inc., whose Investigational New Drug (IND) application was recently cleared by the FDA, enabling the start of phase 1 clinical trials for its lead oncology drug candidate, XMT-1522. The compound is Mersana’s first pipeline product and defines a new class of HER2-targeted therapies. “XMT-1522 represents a promising therapeutic approach for cancer patients with significant unmet medical needs and we are pleased to be in a position to move this therapy into clinical development.” Donald A. Bergstrom,…

ThursdayOct 27, 2016 12:24 pm

3 Business Strategies Driving Moxian, Inc.’s (MOXC) Success in New Media Marketing

China-based Moxian (OTCQB: MOXC) provides some of the biggest interactive marketing products of the mobile Internet era. The competitive nature of the broader technology sector keeps the company on its toes, and company CEO James Tan keeps Moxian firing on all cylinders with a sharp focus on accurately identifying demand, prioritizing quality over quantity, and developing the infrastructure necessary to meet demand. “Over the years, the thriving new media market has given rise to a fast-growing net advertising sector in China and the rest of the world. In China alone, the advertising market is expected to hit around $80 billion…

WednesdayOct 26, 2016 1:49 pm

Cemtrex, Inc. (CETX) Preliminary FY2016 Results Drive Shares Higher

Shares of Cemtrex (NASDAQ: CETX) are 10% higher in mid-day trade after the industrial and manufacturing solutions company announced preliminary financial results for the fiscal year ended September 30, 2016. Cemtrex said it expects revenues in the range of $93 million to $95 million compared to revenues of $56 million in fiscal 2015; net income in the range of $4.8 million to $5.0 million compared to net income of $2.8 million in fiscal 2015; and EBITDA in the range of $6.6 million to $7.0 million compared to $3.9 million a year ago. EPS is expected to increase to $0.52 per…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks